Prichard David, Norton Christine, Bharucha Adil E
Senior Associate Consultant, Division of Gastroenterology, Mayo Clinic Health System La Crosse, Wisconsin, USA.
Professor of Clinical Nursing Practice Research, Florence Nightingale Foundation, King's College London, UK.
Br J Nurs. 2016;25(10):S4-5, S8-11. doi: 10.12968/bjon.2016.25.10.S4.
Up to 40% of patients taking opioids develop constipation. Opioid-induced constipation (OIC) may limit the adequate dosing of opioids for pain relief and reduce quality of life. Health professionals must therefore inquire about bowel function in patients receiving opioids. The management of OIC includes carefully re-evaluating the necessity, type and dose of opioids at each visit. Lifestyle modification and alteration of aggravating factors, the use of simple laxatives and, when essential, the addition of newer laxatives or opioid antagonists (naloxone, naloxegol or methylnaltrexone) can be used to treat OIC. This review discusses the recent literature regarding the management of OIC and provides a rational approach to assessing and managing constipation in individuals receiving opioids.
服用阿片类药物的患者中,高达40%会出现便秘。阿片类药物引起的便秘(OIC)可能会限制用于缓解疼痛的阿片类药物的适当剂量,并降低生活质量。因此,医疗专业人员必须询问接受阿片类药物治疗的患者的肠道功能。OIC的管理包括在每次就诊时仔细重新评估阿片类药物的必要性、类型和剂量。改变生活方式和消除加重因素、使用简单的泻药,以及在必要时添加新型泻药或阿片类拮抗剂(纳洛酮、纳洛西醇或甲基纳曲酮)可用于治疗OIC。本综述讨论了关于OIC管理的最新文献,并提供了一种合理的方法来评估和管理接受阿片类药物治疗的个体的便秘。